Lisinopril compositions with an ingestible event marker

Patent metadata

Field	Value
Publication number	US-11684605-B2
Application number	US-202117495773-A
Country	US
Kind code	B2
Filing date	Oct 6, 2021
Priority date	Apr 25, 2017
Publication date	Jun 27, 2023
Grant date	Jun 27, 2023

Abstract

Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

First claim

What is claimed is:

1. An ingestible composition comprising:
1) about 10% w/w lisinopril;
about 15% w/w dicalcium phosphate, dihydrate;
about 53.85% w/w mannitol (50 um);
about 10% w/w pregelatinized starch; OR

2) about 7.3% w/w lisinopril;
about 30% w/w dicalcium phosphate, dihydrate;
about 24.6% w/w mannitol (50 um);
about 20% w/w pregelatinized starch; OR

3) about 10.21% w/w lisinopril;
about 15.31% w/w dicalcium phosphate, dihydrate;
about 58.02% w/w mannitol (180 um);
about 15.31% w/w pregelatinized starch; OR

4) about 9.69% w/w lisinopril;
about 14.53% w/w dicalcium phosphate, dihydrate;
about 55.09% w/w mannitol (180 um);
about 14.53% w/w pregelatinized starch; OR

5) about 9.18% w/w lisinopril;
about 13.76% w/w dicalcium phosphate, dihydrate;
about 52.16% w/w mannitol (180 um);
about 13.76% w/w pregelatinized starch; OR

6) about 18.18% w/w lisinopril;
about 1318% w/w dicalcium phosphate, dihydrate;
about 47.59% w/w mannitol (50 um);
about 10% w/w pregelatinized starch; OR

7) about 18.18% w/w lisinopril;
about 14.32% w/w dicalcium phosphate, dihydrate;
about 51.36% w/w mannitol (50 um);
about 5% w/w pregelatinized starch; OR

8) about 7.27% w/w lisinopril;
about 30% w/w dicalcium phosphate, dihydrate;
about 24.58% w/w mannitol (50 um);
about 20% w/w pregelatinized starch; OR

9) about 10% w/w lisinopril;
about 28% w/w dicalcium phosphate, dihydrate;
about 22.85% w/w mannitol (50 um);
about 20% w/w pregelatinized starch; OR

10) about 10.26% w/w lisinopril;
about 15.38% w/w dicalcium phosphate, dihydrate;
about 58.32% w/w mannitol (180 um);
about 15.38% w/w pregelatinized starch; OR

11) about 10.16% w/w lisinopril;
about 15.23% w/w dicalcium phosphate, dihydrate;
about 57.73% w/w mannitol (180 um);
about 15.23% w/w pregelatinized starch; OR

12) about 10.05% w/w lisinopril;
about 15.07% w/w dicalcium phosphate, dihydrate;
about 57.14% w/w mannitol (180 um);
about 15.07% w/w pregelatinized starch; OR

13) about 10.1% w/w lisinopril;
about 15.15% w/w dicalcium phosphate, dihydrate;
about 57.44% w/w mannitol (180 um);
about 15.15% w/w pregelatinized starch; OR

14) about 10% w/w lisinopril;
about 15% w/w dicalcium phosphate, dihydrate;
about 56.85% w/w mannitol (180 um);
about 15% w/w pregelatinized starch; OR

15) about 9.74% w/w lisinopril;
about 14.61% w/w dicalcium phosphate, dihydrate;
about 55.39% w/w mannitol (180 um);
about 14.61% w/w pregelatinized starch; OR

16) about 10.62% w/w lisinopril;
about 15.92% w/w dicalcium phosphate, dihydrate;
about 57.18% w/w mannitol (180 um);
about 10.62% w/w pregelatinized starch; OR

17) about 10.06% w/w lisinopril;
about 15.08% w/w dicalcium phosphate, dihydrate;
about 54.16% w/w mannitol (180 um);
about 10.06% w/w pregelatinized starch; and

an ingestible identifier comprising:
an integrated circuit comprising silicon, aluminum, silicon dioxide, and silicon nitride;
a wafer comprising titanium, titanium-tungsten, gold, magnesium, copper (I) chloride, and hydroxypropyl cellulose; and
a skirt film comprising ethyl cellulose, hydroxypropyl cellulose, and triethyl citrate.

2. The ingestible composition of claim 1 , wherein the ingestible composition further comprises iron oxide yellow or water, or both.

3. The ingestible composition of claim 1 , wherein the ingestible composition comprises about 0.10% to about 0.20% w/w iron oxide yellow.

4. The ingestible composition of claim 1 , wherein the ingestible composition comprises about 0.10% to about 0.15% w/w iron oxide yellow.

5. The ingestible composition of claim 1 , wherein the ingestible composition comprises about 0.15% to about 0.20% w/w iron oxide yellow.

6. The ingestible composition of claim 1 , wherein the ingestible composition comprises about 0.15% w/w iron oxide yellow.

7. The ingestible composition of claim 1 , wherein the ingestible composition comprises:
about 0% to about 30.0% w/w microcrystalline cellulose;
about 0% to about 2.5% w/w croscarmellose sodium;
about 0% to about 0.20% w/w iron oxide; and
about 0% to about 0.30% w/w FD&C yellow #6.

8. The ingestible composition of claim 7 , wherein the comprises about 0 or 16% w/w microcrystalline cellulose.

9. The ingestible composition of claim 8 , wherein the ingestible composition comprises about 0 or 2% w/w croscarmellose sodium.

10. The ingestible composition of claim 9 , wherein the ingestible composition comprises about 0.14 or 0.15% w/w iron oxide.

11. The ingestible composition of claim 10 , wherein the ingestible composition comprises about 0% w/w FD&C yellow #6.

Assignees

• Otsuka Pharma Co Ltd

Inventors

• Scheinpflug Kurt
• Pargaonkar Nikhil
• Dong Chris
• Ching Ai Ling
• Adkin Dawn

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61B2560/0204

  of power management · CPC title

• A61K49/00

  Preparations for testing in vivo · CPC title

• A61B5/068

  using impedance sensors · CPC title

• A61B2562/12

  Manufacturing methods specially adapted for producing sensors for in-vivo measurements · CPC title